UBS Initiates Coverage On Amneal Pharmaceuticals with Buy Rating, Announces Price Target of $19
Benzinga Newsdesk 6 months ago
NewsPrice TargetInitiationAnalyst Ratings
UBS analyst Ashwani Verma initiates coverage on Amneal Pharmaceuticals (NASDAQ:AMRX) with a Buy rating and announces Price Target of $19.
UBS analyst Ashwani Verma initiates coverage on Amneal Pharmaceuticals (NASDAQ:AMRX) with a Buy rating and announces Price Target of $19.